Barclays Maintains Equal-Weight on Summit Therapeutics, Lowers Price Target to $18

Benzinga · 3d ago
Barclays analyst Etzer Darout maintains Summit Therapeutics (NASDAQ:SMMT) with a Equal-Weight and lowers the price target from $20 to $18.